RESEARCHERS at Flinders University in Western Australia have developed a new antibiotic which is being claimed as a breakthrough in the war against drug-resistant "superbugs".
Ramizol is the subject of a paper recently published in the Scientific Reports journal, detailing research undertaken jointly by Flinders University, US-based Product Safety Labs and Tox Strategies plus Boulos & Cooper Pharmaceuticals.
Dr Ramiz Boulos, CEO of Boulos & Cooper Pharmaceuticals and adjunct research associate at Flinders, said testing in hamsters found Ramizol had been successfully used to treat clostridium difficile infection (CDI), which was becoming resistant to traditional antibiotics.
Various strains of C.difficile have emerged over the last decade, with one in particular easily transmitted between people and responsible for large outbreaks in hospitals in the USA and Europe.
CDI is the most likely cause of diarrhoea for patients and staff in hospitals, and is one of the most common hospital-acquired infections.
The study can be downloaded at no charge at nature.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jan 19
